Adjunctive therapy with bromocriptine in Parkinson's disease.
Patients with moderately severe Parkinson's disease complicated by the adverse effects of chronic levodopa use benefited from the addition of bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily, which allowed an approximate 30% reduction of levodopa dose. This resulted in a significant decrease in the amount of levodopa side-effects while maintaining or improving the original parkinsonian clinical stage. Increased effectiveness in these patients was not associated with increased dosage beyond 25-30 mg daily. When the doses of bromocriptine were increased slowly, the adverse reactions were minor and usually transient.
Temlett
J A
JA
Neurology Unit, Johannesburg Hospital.
Ming
A
A
Saling
M
M
Fritz
V U
VU
Blumenfeld
A
A
Bilchik
T R
TR
Becker
A L
AL
Fourie
P B
PB
Reef
H E
HE
D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D001971:Bromocriptine; D007980:Levodopa